CRISPR Therapeutics saw the highest growth of 1.32% in patent filings and 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and grants by 0.66%. GlobalData’s DataBook provides a comprehensive analysis of CRISPR Therapeutics‘s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
CRISPR Therapeutics has been focused on protecting inventions in United States(US) with six publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 44% filings and 40% grants. The United States(US), World Intellectual Property Organization(WIPO), European Patent Office(EPO), and Australia(AU) patent Office are among the top ten patent offices where CRISPR Therapeutics is filings its patents. Among the top granted patent authorities, CRISPR Therapeutics has 40% of its grants in United States(US), 20% in European Patent Office(EPO) and 20% in Australia(AU).
Regeneron Pharmaceuticals and Massachusetts Institute of Technology could be the strongest competitors for CRISPR Therapeutics
In terms of grant share, CRISPR Therapeutics stands in fifth position among its competitors. Regeneron Pharmaceuticals and Massachusetts Institute of Technology secured the top positions according to recent patent publication data.
Patents related to rare diseases and cell & gene therapy lead CRISPR Therapeutics's portfolio
CRISPR Therapeutics has the highest number of patents in rare diseases followed by, cell & gene therapy and genomics. For rare diseases, nearly 31% of patents were filed and 29% of patents were granted in Q2 2024.
Cell therapy related patents lead CRISPR Therapeutics portfolio followed by hemoglobinopathies, and hemophilia a (factor viii deficiency)
CRISPR Therapeutics has highest number of patents in cell therapy followed by hemoglobinopathies, hemophilia a (factor viii deficiency), glycogen storage disease 1a, and cytokine release syndrome (cytokine storm). For cell therapy, nearly 5% of patents were filed and 7% of patents were granted in Q2 2024.
For comprehensive analysis of CRISPR Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
